Arca
Skip to content

Cardiovascular disease

Drug research and approvals for cardiovascular disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 8,110 studies of cardiovascular disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 53 drug trials for it since 2013, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 8,110
  • Trials authorized in Canada: 53
  • FDA orphan approvals: 0
  • EU medicines: 4

Recruiting Now

Newest start dates first, of 8,110 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 53; search them all in Canada trials
Aug 20, 2026A phase III, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of once weekly petrelintide vs. placebo in…PETRELINTIDE (RO7895515)RochePending
Aug 6, 2026Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either…ZENAGAMTIDE INJECTIONNovo NordiskOngoing
Sep 22, 2025Zenith: a phase 3 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zilebesiran in addition to standard of care…ZILEBESIRAN (ALN-AGT01)Alnylam PharmaceuticalsOngoing
Sep 22, 2025A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of orforglipron on the incidence of major adverse…ORFORGLIPRON (LY3502970)Eli LillyOngoing
Jul 22, 2025A phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of muvalaplin on the reduction of major adverse cardiovascular events…MUVALAPLIN (LY3473329)Eli LillyOngoing
Jun 26, 2025A phase 3 randomized, double-blind, placebo-controlled study to evaluate the impact of maridebart cafraglutide on cardiovascular outcomes in participants with…MARIDEBART CAFRAGLUTIDE (AMG 133)AmgenOngoing
Jun 13, 2025A phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (bi 690517) and…VICADROSTAT (BI 690517) / EMPAGLIFLOZIN (BI 10773)Boehringer Ingelheim Pharmaceuticals, Inc.Ongoing
Jun 12, 2025A single arm, multicenter, open-label extension (ole) trial to evaluate long-term safety and tolerability of pelacarsen (tqj230) in participants who completed…PELACARSEN (TQJ230)Novartis Pharmaceuticals CorporationOngoing
Jun 5, 2025A double-blind, randomized, placebo-controlled, multi-center study evaluating the safety, tolerability, and effect of olpasiran on coronary artery plaque…OLPASIRAN (AMG 890)AmgenOngoing
May 16, 2025A phase III, randomized, double-blind, placebo-controlled, parallel-group study to assess the effect of azd0780 on major adverse cardiovascular events in…LAROPROVSTAT (AZD0780)AstraZeneca Pharmaceuticals LPOngoing

Medicines Authorised in the EU

Newest first
Sep 29, 2010Telmisartan Actavistelmisartan · genericActavis Group PTC ehfEMA ↗
Jun 4, 2010Toluratelmisartan · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Dec 16, 1998MicardistelmisartanBoehringer Ingelheim International GmbHEMA ↗
May 17, 1998OptisonperflutrenGE Healthcare ASEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.